Search the Newsreel

Earnings call transcript: Neuronetics tops Q2 2026 forecasts as stock jumps 23%

Neuronetics publishes investor presentation on NeuroStar TMS, Greenbrook clinic network strategy

Neuronetics has released an investor presentation detailing its NeuroStar TMS and Greenbrook clinic network strategy. The company provided FY 2026 revenue guidance of $160 million to $164 million, projecting 7% to 10% year-on-year growth, alongside a gross margin outlook of 48% to 50%. It …

Neuronetics STIM Draws Buy Rating As Vertical Psychiatry Platform Scales Up

Neuronetics (STIM) has received a "Buy" rating and a $5 target price from BTIG, signaling bullish sentiment due to its expanding depression-treatment technology adoption and vertically integrated psychiatry platform. The company's acquisition of 93 Greenbrook-operated treatment centers and the establishment of a National Center …

Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates

NeuroOne(R) Achieves Major Milestone With ISO 13485 Certification

NeuroOne Medical Technologies Corporation has announced it received ISO 13485-2016 certification, an international standard for Quality Management Systems in the Medical Device Industry. This certification allows NeuroOne to pursue international marketing opportunities for its Evo® Cortical and Evo® sEEG Electrodes, and the OneRF® Brain …

Firefly Neuroscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Neuronetics stock soars 15% on second quarter earnings beat

Neuronetics (NASDAQ:STIM) reported strong second-quarter results, surpassing analyst expectations with an adjusted loss per share of -$0.05 and revenue of $41.6 million. The company's stock surged over 15% in pre-market trading, driven by a 9.1% year-over-year revenue increase, primarily from its Greenbrook clinic segment. …

Neuronetics Reports Second Quarter 2026 Results, Highlights Revenue Growth and Improved Adjusted EBITDA

Neuronetics, Inc. reported a 9.1% increase in total revenue to $41.6 million for Q2 2026, driven by a 16.8% rise in Greenbrook healthcare clinic revenue. The company also significantly improved its adjusted EBITDA to $0.3 million and reduced its net loss to $3.4 million. …

Neurogene: Q2 Earnings Snapshot

Neuronetics (STIM) Earnings Date and Reports 2026 $STIM

Neurogene (NGNE) Earnings Date and Reports 2026

ClearPoint Neuro (CLPT) Q2 2026 Earnings Call Transcript

Is Neurocrine Biosciences (NBIX) Fully Valued As It Enters Phase 1 Obesity Testing?

Neurocrine Biosciences (NBIX) has commenced a Phase 1 study for its obesity treatment candidate, NBIP 1968, following positive Q2 and H1 2026 financial results. Despite recent stock momentum and a current share price of $163.41, Simply Wall St's analysis suggests the company might be …

NewMarket Corp stock hits all-time high at 901.27 USD

NewMarket Corp (NEU) stock has reached an all-time high of $901.27, currently trading at $904.16 with a year-to-date return of 30.6%. Despite this strong performance and being near its 52-week high, InvestingPro analysis suggests the stock may be overvalued and in overbought territory. The …

ProMIS Neurosciences Inc (PMN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Neurogene Inc (NGNE) Earnings Forecast: Future EPS & Revenue Growth Estimates

NewMarket Corp (NEU) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for NewMarket Corp (NEU), detailing its future EPS and revenue growth estimates. It includes current stock information, market capitalization, P/E ratio, and lists peer companies with their analyst ratings. The forecast was updated on August 9, 2026.

WaveDancer, Inc. Releases 2023 10-K Report Highlighting Strategic Shifts and Financial Performance

WaveDancer, Inc. has released its 2023 Form 10-K report, detailing a 27.6% revenue decrease to $8.0 million, alongside a significant reduction in net loss to $2.0 million. The company is strategically shifting its focus from IT consulting towards AI-driven Brain Network Analytics through a …

Is NewMarket (NEU) Undervalued After Strong Second Quarter Earnings?

Price to earnings forward of Neutech Group Limited – HKEX:9616

NewMarket Corp (NEU) Stock Forecasts

Argus has raised its target price for NewMarket Corp (NEU) to $933.00, up from its current price of $889.71. NewMarket Corp is a holding company specializing in the manufacturing and sale of petroleum additives. The report, dated August 05, 2026, also mentions similar target …

Minerva Neurosciences (NASDAQ:NERV) Upgraded at Wall Street Zen

Wall Street Zen upgraded Minerva Neurosciences (NASDAQ:NERV) from a "sell" to a "hold" rating. The biopharmaceutical company reported a quarterly loss of $0.14 per share, surpassing analyst expectations for a $0.19 loss. Despite the upgrade, NERV shares were trading down 3.8% at $4.27, well …

NeuroPace, Inc. expected to post a loss of 21 cents a share - Earnings Preview

NeuroPace, Inc. is projected to report a loss of 21 cents per share, according to this earnings preview. The article indicates that this financial outlook is based on information from Refinitiv. Full article access requires a TradingView subscription.

Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Cetera Investment Advisers

Cetera Investment Advisers significantly increased its stake in Neurocrine Biosciences (NBIX) by 50.1% in the first quarter, now owning 20,245 shares valued at $2.67 million. Institutional investors hold 92.59% of NBIX. Despite insider sales totaling over $62 million in the past quarter, analysts maintain …

Neuland Laboratories gains after robust quarterly surge and fresh capacity bets

Neuland Laboratories Limited Beat Revenue Forecasts By 23%: Here's What Analysts Are Forecasting Next

NewMarket Corp (NEU) Stock News Today

This article provides current stock information for NewMarket Corp (NEU), including its stock price, market capitalization, and P/E ratio. It indicates that more news will be available soon and offers various market data points and navigational links for investors.

Neurocrine Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:NBIX) 2026-08-07

This article announces that Neurocrine Biosciences, Inc. (NBIX) has published its slide deck in conjunction with its Q2 2026 earnings call. The earnings call presentation was made on August 7, 2026. The article was written by the Seeking Alpha Transcripts team, which regularly publishes …

Neurocrine Biosciences, Inc. $NBIX Stake Boosted by PKO BP BANKOWY Universal Pension Society JSC

PKO BP BANKOWY Universal Pension Society JSC significantly increased its stake in Neurocrine Biosciences (NASDAQ:NBIX) by 23.1% in the second quarter, now holding 170,802 shares valued at $28.8 million. This move highlights continued institutional investor interest, with several other hedge funds also boosting their …

Form 8K Minerva Neurosciences Inc For: 7 August By Investing.com

This article reports on the filing of a Form 8K by Minerva Neurosciences Inc. on August 7. It includes a brief mention of the company's stock symbol and a slight decrease in its share price. The content primarily serves as an announcement for the …

Minerva Neurosciences posts Q2 2026 results: GAAP net income $17.5M; cash & equivalents $75.4M

Minerva Neurosciences reported a GAAP net income of $17.5 million for Q2 2026, largely due to a non-cash gain on a warrant liability, with cash and equivalents standing at $75.4 million. The company is advancing a global confirmatory Phase 3 trial for roluperidone, with …

Enterprise value to EBIT forward of Neuropace, Inc. – NASDAQ:NPCE

This article provides a financial data point for Neuropace, Inc. (NASDAQ: NPCE), specifically its enterprise value to EBIT forward. It appears to be a financial snapshot from TradingView, indicating the company's financial metrics. The content is sparse, primarily focusing on this single financial ratio …

ETFs Investing in Neurocrine Biosciences, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Neurocrine Biosciences, Inc. The list, sorted by market value, provides details such as market value, weight, issuer, management style, expense ratio, assets under management (AUM), price, change, relative volume, and 3-year NAV …

How Stronger Q2 Results and New Equity Capacity Will Impact Neurocrine Biosciences (NBIX) Investors

Neurocrine Biosciences recently reported strong Q2 2026 results, with significant revenue and net income, alongside a new equity shelf registration tied to an ESOP offering. This dual development highlights the company's efforts to strengthen employee ownership and financial flexibility. The article discusses how these …

ClearPoint Neuro (NASDAQ:CLPT) Downgraded to "Strong Sell" Rating by Wall Street Zen

Wall Street Zen has downgraded ClearPoint Neuro (NASDAQ:CLPT) to a "strong sell" rating, despite other analysts having a mixed view with a consensus "Hold" rating and a target price of $25.67. The downgrade follows ClearPoint Neuro missing its quarterly earnings expectations, reporting an adjusted …

Minerva Neurosciences (NASDAQ:NERV) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS